ClinicalTrials.gg
CompletedNCT02573233EXPEDITIONUpdated Apr 4, 2022Results posted

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

A Phase 2 interventional study of Placebo and Dupilumab SAR231893/REGN668 in Asthma, sponsored by Sanofi. Completed at 16 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-04-04.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
24th of 31
42 · median 120
Started
2016
the only one that year
Phase 2
5 of 31
none open now
Registered
6th of 31
by date
Lead sponsor
15 of 31
Sanofi

Among the 31 studies testing dupilumab in Asthma, this one is the 24th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 2, and was the 6th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the effect of dupilumab, compared to placebo, on airway inflammation in participants with persistent asthma.

Secondary Objective:

To assess the safety, tolerability, and immunogenicity of dupilumab compared to placebo.

Read the detailed description

The total study duration for each participant was between approximately 29 and maximum of 30 weeks, consisting of a screening period of 5 weeks and optional up to 7 additional days, a treatment period of 12 weeks, and a post-treatment period of 12 weeks.

Participants who completed the treatment period could be eligible to participate in an open-label extension study.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female adults with a physician diagnosis of persistent asthma for ≥12 months.
  • Existing treatment with medium to high dose inhaled in combination with a long-acting beta agonist for at least 3 months with a stable dose ≥1 month prior to Visit 1 (Screening Visit).
  • Treatment with a third asthma controller for at least 3 months with a stable dose >=1 month prior to Visit 1 was allowed.
  • Pre-bronchodilator (FEV1) 55 to 85% of predicted normal.

Exclusion criteria

Exclusion criteria:

  • Participants \<18 years or >65 years.
  • Fractional exhaled nitric oxide (FeNO) \<26 parts per billion (ppb) at Visit 1 (Screening Visit).
  • or other lung diseases (eg, idiopathic pulmonary fibrosis, eosinophilic granulomatosis with polyangiitis [Churg-Strauss Syndrome]) which could impair lung function.
  • A participant who experienced an asthma exacerbation that resulted in emergency treatment, hospitalization due to asthma, or treatment with systemic at any time from 1 month prior to Visit 1.
  • A participant who had experienced an upper or lower respiratory tract infection within the 4 weeks prior to Visit 1.
  • Evidence of lung disease(s) other than asthma.
  • Previous smoker (smoking history >10 pack-years) or current smoker (within 6 months prior to Visit 1).
  • Comorbid disease that might interfere with the evaluation of medicinal product or conduct of study procedures (e.g., bronchoscopy).
  • Anti-immunoglobulin E (IgE) therapy (omalizumab) or any other biologic therapy within 6 months of Visit 1.
  • Exposure to another investigative study medication within a time period prior to Visit 1 that is less than 5 half-lives of the study medication.
  • Treatment with systemic (oral or injectable) corticosteroids within 28 days of Visit 1.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
42 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo (for dupilumab), 2 subcutaneous injections on Day 1 (Week 1) as a loading dose followed by a single injection q2w from Week 2 to Week 14, added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.

    Drug: Placebo · Drug: fluticasone propionate and salmeterol · Drug: budesonide and formoterol · Drug: mometasone furoate and formoterol

  • Experimental
    Dupilumab

    Dupilumab, 2 subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection q2w from Week 2 to Week 14, added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.

    Drug: Dupilumab SAR231893/REGN668 · Drug: fluticasone propionate and salmeterol · Drug: budesonide and formoterol · Drug: mometasone furoate and formoterol

Interventions

  • DrugPlacebo

    Pharmaceutical form:solution Route of administration: subcutaneous

  • DrugDupilumab SAR231893/REGN668

    Drug page: Dupilumab

    Pharmaceutical form:solution Route of administration: subcutaneous

  • Drugfluticasone propionate and salmeterol

    Drug pages: Fluticasone · Salmeterol Xinafoate

    Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled

    Also known as: Advair

  • Drugbudesonide and formoterol

    Drug pages: Budesonide · Formoterol

    Pharmaceutical form:inhalation aerosol Route of administration: inhaled

    Also known as: Symbicort

  • Drugmometasone furoate and formoterol

    Drug pages: Mometasone Furoate · Formoterol

    Pharmaceutical form:inhalation aerosol Route of administration: inhaled

    Also known as: Dulera

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Eosinophils Cells Count in the Bronchial Submucosa at Week 12

    Inflammatory cells i.e. eosinophils were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.

    Time frame: Baseline, Week 12

  2. Change From Baseline in Mucin-Stained Area in the Bronchial Submucosa at Week 12

    Mucin was identified by staining with Alcian-blue periodic acid-Schiff and/or immunostaining for MUC5AC and then the mucin-positive area was measured and expressed per square millimeter.

    Time frame: Baseline, Week 12

  3. Change From Baseline in Mast Cells Count (Chymase Positive) in the Bronchial Submucosa at Week 12

    Inflammatory cells i.e. mast cells were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.

    Time frame: Baseline, Week 12

  4. Change From Baseline in Mast Cells Count (Tryptase Positive) in the Bronchial Submucosa at Week 12

    Inflammatory cells i.e. mast cells were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.

    Time frame: Baseline, Week 12

  5. Change From Baseline in T-Lymphocytes Count in the Bronchial Submucosa at Week 12

    T-Lymphocytes i.e. CD3 positive cells were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.

    Time frame: Baseline, Week 12

  6. Change From Baseline in T-Helper Lymphocytes Count in the Bronchial Submucosa at Week 12

    T-helper i.e. CD4 positive lymphocytes were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 12

    FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/second, and reported in ppb.

    Time frame: Baseline, Week 12

  2. Average Change in Fractional Exhaled Nitric Oxide (FeNO) From Baseline to Week 6 Through Week 12

    FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/s, and reported in ppb. The average change in FeNO from baseline to Week 6 through Week 12 was calculated as follows: For each participant the change in FeNO from Baseline to Week 6, Week 8, Week 10 and Week 12 was calculated (value at Week X - value at baseline). Subsequently the weekly mean of these 4 "change from baseline" values was determined (Weeks 6, 8, 10 and 12). Using these weekly mean values the overall arithmetic mean and standard deviation of the average change in FeNO from baseline to Week 6 through Week 12 was calculated.

    Time frame: From Baseline to Week 6 through Week 12

  3. Number of Participants With Antidrug Antibodies (ADA)

    Anti-drug antibodies were detected using a validated immunoassay. Incidence of ADA were classified as following: 1) Pre-existing immunoreactivity - an ADA positive response in the assay at baseline with all post treatment ADA results negative or an ADA positive response at baseline with all post treatment ADA responses less than 4-fold over baseline titer levels. 2) Treatment-emergent ADA: an ADA positive response in the assay post first dose, when baseline results were negative or missing. 3) Treatment-boosted ADA: an ADA positive response in the assay post first dose that was greater-than or equal to 4-fold over baseline titer levels, when baseline results were positive.

    Time frame: From Baseline up to 24 weeks

  4. Pharmacokinetics (PK) Assessment: Serum Functional Dupilumab Concentration

    Serum functional dupilumab concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) method.

    Time frame: Week 0, Week 2, 6, 8, 12, 18, End of study (Week 24)

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Adverse event (AE) was defined as any untoward medical occurrence in a participant who received investigational medicinal product (IMP) without regard to possibility of causal relationship with this treatment. TEAEs: AEs that developed or worsened or became serious during between the first administration of study medication to the end of the 12 week Post-treatment Period. Serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included both serious and non-serious AEs.

    Time frame: Baseline up to Week 24

07

Results

Posted Jan 28, 2019

Participant flow

The study was conducted at 16 sites in 6 countries. A total of 133 participants were screened between January 2016 and January 2018. Of which, 42 participants were randomized. 91 participants were screen failures mainly due to exclusion criteria met and inclusion criteria not met.

Participant flow — Overall Study
MilestonePlaceboDupilumab
Started2220
Completed2220
Not completed00

Outcome measures

PrimaryChange From Baseline in Eosinophils Cells Count in the Bronchial Submucosa at Week 12

Inflammatory cells i.e. eosinophils were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.

Time frame:
Baseline, Week 12
Reported as:
Median · cells/mm^2
Change From Baseline in Eosinophils Cells Count in the Bronchial Submucosa at Week 12
cells/mm^2PlaceboDupilumab
Change From Baseline in Eosinophils Cells Count in the Bronchial Submucosa at Week 125.80 (-9.18 to 33.41)-6.04 (-174.71 to 19.41)
Statistical analysis
  • Placebo vs Dupilumab · Rank ANCOVA · p = 0.8400 (Threshold for significance at 0.05 level)Rank ANCOVA model stratified by ICS dose level and region
PrimaryChange From Baseline in Mucin-Stained Area in the Bronchial Submucosa at Week 12

Mucin was identified by staining with Alcian-blue periodic acid-Schiff and/or immunostaining for MUC5AC and then the mucin-positive area was measured and expressed per square millimeter.

Time frame:
Baseline, Week 12
Reported as:
Mean · cells/mm^2
Change From Baseline in Mucin-Stained Area in the Bronchial Submucosa at Week 12
cells/mm^2PlaceboDupilumab
Change From Baseline in Mucin-Stained Area in the Bronchial Submucosa at Week 1264.09 ± 391.96-142.74 ± 477.89
Statistical analysis
  • Placebo vs Dupilumab · Linear fixed-effect model · p = 0.0336 (Threshold for significance at 0.05 level) · Ls mean difference: -235.02 · 90% CI -414.19 to -55.84
PrimaryChange From Baseline in Mast Cells Count (Chymase Positive) in the Bronchial Submucosa at Week 12

Inflammatory cells i.e. mast cells were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.

Time frame:
Baseline, Week 12
Reported as:
Mean · cells/mm^2
Change From Baseline in Mast Cells Count (Chymase Positive) in the Bronchial Submucosa at Week 12
cells/mm^2PlaceboDupilumab
Change From Baseline in Mast Cells Count (Chymase Positive) in the Bronchial Submucosa at Week 12-14.80 ± 76.521.76 ± 62.41
Statistical analysis
  • Placebo vs Dupilumab · Linear fixed-effect model · p = 0.4795 (Threshold for significance at 0.05 level.) · Ls mean difference: 13.89 · 90% CI -19.00 to 46.78
PrimaryChange From Baseline in Mast Cells Count (Tryptase Positive) in the Bronchial Submucosa at Week 12

Inflammatory cells i.e. mast cells were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.

Time frame:
Baseline, Week 12
Reported as:
Mean · cells/mm^2
Change From Baseline in Mast Cells Count (Tryptase Positive) in the Bronchial Submucosa at Week 12
cells/mm^2PlaceboDupilumab
Change From Baseline in Mast Cells Count (Tryptase Positive) in the Bronchial Submucosa at Week 122.37 ± 90.20-20.89 ± 59.09
Statistical analysis
  • Placebo vs Dupilumab · Linear fixed-effect model · p = 0.4494 (Threshold for significance at 0.05 level.) · Ls mean difference: -18.98 · 90% CI -60.92 to 22.97
PrimaryChange From Baseline in T-Lymphocytes Count in the Bronchial Submucosa at Week 12

T-Lymphocytes i.e. CD3 positive cells were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.

Time frame:
Baseline, Week 12
Reported as:
Median · cells/mm^2
Change From Baseline in T-Lymphocytes Count in the Bronchial Submucosa at Week 12
cells/mm^2PlaceboDupilumab
Change From Baseline in T-Lymphocytes Count in the Bronchial Submucosa at Week 12-36.70 (-200.25 to 267.51)34.21 (-95.08 to 232.99)
Statistical analysis
  • Placebo vs Dupilumab · Rank ANCOVA · p = 0.6865 (Threshold for significance at 0.05 level.)Rank ANCOVA model stratified by ICS dose level and region
PrimaryChange From Baseline in T-Helper Lymphocytes Count in the Bronchial Submucosa at Week 12

T-helper i.e. CD4 positive lymphocytes were counted in the bronchial submucosa of biopsy thin sections using quantitative immunohistochemistry and reported as the number of cells per square millimeter.

Time frame:
Baseline, Week 12
Reported as:
Median · cells/mm^2
Change From Baseline in T-Helper Lymphocytes Count in the Bronchial Submucosa at Week 12
cells/mm^2PlaceboDupilumab
Change From Baseline in T-Helper Lymphocytes Count in the Bronchial Submucosa at Week 127.26 (-179.43 to 224.96)62.34 (-100.62 to 159.09)
Statistical analysis
  • Placebo vs Dupilumab · Rank ANCOVA · p = 0.7588 (Threshold for significance at 0.05 level)Rank ANCOVA model stratified by ICS dose level and region
SecondaryChange From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 12

FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/second, and reported in ppb.

Time frame:
Baseline, Week 12
Reported as:
Mean · ppb
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 12
ppbPlaceboDupilumab
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 123.9 ± 22.8-15.1 ± 18.3
Statistical analysis
  • Placebo vs Dupilumab · MMRM · p = 0.0012 (Threshold for significance at 0.05 level) · Ls mean difference: -22.4 · 90% CI -32.9 to -11.9
SecondaryAverage Change in Fractional Exhaled Nitric Oxide (FeNO) From Baseline to Week 6 Through Week 12

FeNO is a surrogate marker for airway inflammation. FeNO was analyzed using a NIOX instrument or similar analyzer using a flow rate of 50 mL/s, and reported in ppb. The average change in FeNO from baseline to Week 6 through Week 12 was calculated as follows: For each participant the change in FeNO from Baseline to Week 6, Week 8, Week 10 and Week 12 was calculated (value at Week X - value at baseline). Subsequently the weekly mean of these 4 "change from baseline" values was determined (Weeks 6, 8, 10 and 12). Using these weekly mean values the overall arithmetic mean and standard deviation of the average change in FeNO from baseline to Week 6 through Week 12 was calculated.

Time frame:
From Baseline to Week 6 through Week 12
Reported as:
Mean · ppb
Average Change in Fractional Exhaled Nitric Oxide (FeNO) From Baseline to Week 6 Through Week 12
ppbPlaceboDupilumab
Average Change in Fractional Exhaled Nitric Oxide (FeNO) From Baseline to Week 6 Through Week 123.5 ± 18.0-16.0 ± 21.0
Statistical analysis
  • Placebo vs Dupilumab · MMRM · p = 0.0005 (Threshold for significance at 0.05 level) · Ls mean difference: -22.0 · 90% CI -31.3 to -12.8
SecondaryNumber of Participants With Antidrug Antibodies (ADA)

Anti-drug antibodies were detected using a validated immunoassay. Incidence of ADA were classified as following: 1) Pre-existing immunoreactivity - an ADA positive response in the assay at baseline with all post treatment ADA results negative or an ADA positive response at baseline with all post treatment ADA responses less than 4-fold over baseline titer levels. 2) Treatment-emergent ADA: an ADA positive response in the assay post first dose, when baseline results were negative or missing. 3) Treatment-boosted ADA: an ADA positive response in the assay post first dose that was greater-than or equal to 4-fold over baseline titer levels, when baseline results were positive.

Time frame:
From Baseline up to 24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Antidrug Antibodies (ADA)
ParticipantsPlaceboDupilumab
With pre-existing immunoreactivity10
With treatment-emergent ADA01
With treatment-boosted ADA00
SecondaryPharmacokinetics (PK) Assessment: Serum Functional Dupilumab Concentration

Serum functional dupilumab concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) method.

Time frame:
Week 0, Week 2, 6, 8, 12, 18, End of study (Week 24)
Reported as:
Mean · ng/mL
Pharmacokinetics (PK) Assessment: Serum Functional Dupilumab Concentration
ng/mLDupilumab
Week 00.00 ± 0.00
Week 252675.00 ± 23107.55
Week 659969.00 ± 27422.27
Week 861097.95 ± 29775.23
Week 1267387.00 ± 32800.44
Week 1820728.17 ± 17718.93
Week 241851.20 ± 2796.78
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

Adverse event (AE) was defined as any untoward medical occurrence in a participant who received investigational medicinal product (IMP) without regard to possibility of causal relationship with this treatment. TEAEs: AEs that developed or worsened or became serious during between the first administration of study medication to the end of the 12 week Post-treatment Period. Serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included both serious and non-serious AEs.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPlaceboDupilumab
Any TEAE1715
Any treatment emergent SAE01
Any TEAE leading to death00
Any TEAE leading to permanent discontinuation00

Adverse events

Collected over All AEs were collected from signature of the informed consent form up to the end of study (i.e. up to the end of Post-treatment period [Week 24]) regardless of seriousness or relationship to investigational medicinal product (IMP).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/22 (0%)0/22 (0%)11/22 (50%)
Dupilumab0/20 (0%)1/20 (5%)14/20 (70%)
Most frequent serious events
Most frequent serious events
EventPlaceboDupilumab
NeutropeniaBlood and lymphatic system disorders0/221/20
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPlaceboDupilumab
HeadacheNervous system disorders3/225/20
NasopharyngitisInfections and infestations4/222/20
NauseaGastrointestinal disorders1/223/20
Injection Site ErythemaGeneral disorders2/223/20
Upper Respiratory Tract InfectionInfections and infestations1/223/20
Back PainMusculoskeletal and connective tissue disorders0/223/20
VomitingGastrointestinal disorders0/222/20
Injection Site PruritusGeneral disorders1/222/20
Accidental OverdoseInjury, poisoning and procedural complications1/222/20
Road Traffic AccidentInjury, poisoning and procedural complications0/222/20

Baseline characteristics

Baseline population included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboDupilumabTotal
Mean41.0 ± 10.345.5 ± 10.643.1 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDupilumabTotal
Female81321
Male14721
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboDupilumabTotal
Hispanic or Latino112
Not Hispanic or Latino211940
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboDupilumabTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American336
White191635
More than one race000
Unknown or Not Reported000
Baseline Eosinophils Count in Bronchial Tissue
Baseline Eosinophils Count in Bronchial Tissue(cells/mm^2)PlaceboDupilumabTotal
Median12.97 (9.91 to 21.24)34.96 (10.07 to 263.75)20.73 (9.99 to 68.87)
Baseline Mucin-Stained Area in The Bronchial Tissue Specimen
Baseline Mucin-Stained Area in The Bronchial Tissue Specimen(cells/mm^2)PlaceboDupilumabTotal
Mean561.12 ± 289.00520.57 ± 511.69542.33 ± 402.61
Baseline Mast Cells Count (Chymase Positive) in Bronchial Tissue
Baseline Mast Cells Count (Chymase Positive) in Bronchial Tissue(cells/mm^2)PlaceboDupilumabTotal
Mean74.36 ± 58.6379.17 ± 68.0776.59 ± 62.42
Baseline Mast Cells Count (Tryptase Positive) in Bronchial Tissue
Baseline Mast Cells Count (Tryptase Positive) in Bronchial Tissue(cells/mm^2)PlaceboDupilumabTotal
Mean80.10 ± 64.92105.53 ± 104.6891.88 ± 85.49

3 further baseline measures are reported on the registry.

08

Study locations

16 sites
  • Investigational Site Number 840402
    Tucson, Arizona 85724, United States
  • Investigational Site Number 840403
    Denver, Colorado 80206, United States
  • Investigational Site Number 840401
    Boston, Massachusetts 02115, United States
  • Investigational Site Number 840002
    Saint Louis, Missouri 63110, United States
  • Investigational Site Number 840404
    Winston-Salem, North Carolina 27157-1071, United States
  • Investigational Site Number 840028
    Pittsburgh, Pennsylvania 15213, United States
  • Investigational Site Number 124012
    Montreal, H2X 2P4, Canada
  • Investigational Site Number 124018
    Sainte Foy, G1V 4G5, Canada
  • Investigational Site Number 208002
    Hvidovre, 2650, Denmark
  • Investigational Site Number 208001
    København Nv, 2400, Denmark
  • Investigational Site Number 276013
    Frankfurt Am Main, 60596, Germany
  • Investigational Site Number 276011
    Großhansdorf, 22927, Germany
  • Investigational Site Number 276012
    Hannover, 30625, Germany
  • Investigational Site Number 752001
    Lund, 221 85, Sweden
  • Investigational Site Number 826010
    London, W2 1NY, United Kingdom
  • Investigational Site Number 826009
    Oxford, OX3 7LE, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Jan 2018, 23 months.

Results were first posted in Jan 2019, 1 year after primary completion.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 23 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2015
First posted
Oct 9, 2015
StartActual
Jan 27, 2016
Primary completionActual
Jan 3, 2018
CompletionActual
Jan 3, 2018
Results first posted
Jan 28, 2019
Last update
Apr 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02573233
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 9, 2015
Start date
Jan 27, 2016
Primary completion
Jan 3, 2018
Completion
Jan 3, 2018
Results posted
Jan 28, 2019
Last update
Apr 4, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion